PolarityTE has 'solid momentum' heading into 2019, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $30 price target on PolarityTE. Van Buren said that with the addition of 22 reps by year end, the company is "poised to transition the current 366 in-process accounts to active accounts and add to the 56 who are currently using the product." He also believes "data from head-to-head clinical trials will be key and expect to receive several updates throughout the year in the acute, burn and chronic wound care settings." Overall, he sees a solid amount of momentum in PolarityTE entering 2019, and believes the company is on track to achieve $300M+ in SkinTE sales by 2025.